AstraZeneca Pharma shares gain as it receives CDSCO nod for import of endometrial cancer treatment drug

Shares of AstraZeneca Pharma India Ltd. gained on Tuesday, February 10, after the company said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import Imfinzi (durvalumab) solution, indicated for the treatment of endometrial cancer.

In an exchange filing, the pharma firm said the Central Drugs Standard Control Organisation gave its nod for import for sale and distribution of durvalumab solution for infusion 120mg/2.4ml and 500mg/10ml.

"Through this approval, durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer that is mismatch repair-deficient (dMMR)," the company said in an exchange filing.

The approval paves way for the marketing of durvalumab solution for infusion 120mg/2.4ml and 500mg/10ml (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any, it added.

Last month as well, the pharma company had received permission from the CDSCO for Imfinzi or durvalumab solution, indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Shares of AstraZeneca Pharma India Ltd. were trading 2.5% up at 8,889 apiece around 11.09 am on Tuesday. The stock has gained 18% in the past year.

Also Read: RailTel shares jump nearly 8% after bagging ₹4,550 crore West Central Railway order